A Phase 2 interventional study of Pressure Targeted High Flow and CPAP in Preterm Infants, Respiratory Distress Syndrome (Neonatal) and BPD - Bronchopulmonary Dysplasia, sponsored by University of Texas at Austin. Not yet recruiting at 2 sites in United States. Open to participants aged 7 Days to 40 Weeks. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by University of Texas at Austin · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Pulmonary Atelectasis with a site in United States — 11 open to participants now, 11 under way, 1 of them phase 3. Pulmonary Atelectasis · United States.
Among the 43 studies in Pulmonary Atelectasis with a site in United States, this one is the 15th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 2, reaches primary completion later than 4 of the 10 other live ones, and was the 41st registered.
378 studies on the registry are indexed under Pulmonary Atelectasis; 91 are open to participants now.
Browse Pulmonary Atelectasis studies →11 of the 43 studies in Pulmonary Atelectasis with a site in United States are open now. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 0 hrs–72 hrs
University of Texas Southwestern Medical Center · Sites in United States
Ages 0 hrs–3 days
University of Arkansas · Sites in United States
Hackensack Meridian Health · Sites in United States
Ages 34 wk–36 wk
ONY · Sites in United States
Ages 29 wk–36 wk
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Pulmonary Atelectasis studies recruiting now, 20 (39%) set no upper age limit and 23 (45%) stop at 75 or younger; 24 take children under 18; 2 take healthy volunteers.
This study: 7 Days to 40 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 2 · Phase 4 1
First in 2005; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 78 is above the median of 60 across 268 interventional studies indexed under Pulmonary Atelectasis.
Median enrollment 40 across the 37 interventional studies, 300 across the 5 observational. Of the 26 that completed or were terminated, 13 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 43 have an industry lead sponsor. The 10 most frequent:
University of Texas at Austin is the lead sponsor of 328 studies on the registry; 79 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
University of Texas at Austin has 1 study filed under Pulmonary Atelectasis — fewer than ten, so there is no comparison to draw.
5 of the studies in Pulmonary Atelectasis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
| NCT07674953University of ArkansasHow Different Levels of CPAP Affect Oxygen Delivery and Lung Expansion in Preterm Infants | 2026-12 |
| NCT05675345NYU Langone HealthPhysiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure | 2027-06-30 |
| NCT07418502University of Texas at AustinPressure Targeting During High Flow Therapy in Premature Infants | 2027-08 |
| NCT07216053Hackensack Meridian HealthPredictive Value of Lung Ultrasound for Respiratory Decompensation in Late Preterm Neonates | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies in Pulmonary Atelectasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to see if a new approach to breathing support ('Pressure Targeted High Flow') is as effective as standard of care ('Continuous Positive Airway Pressure') in prematurely born infants. It will also learn about the effect of these types of breathing support on infant comfort and impact on staffing. The main question it aims to answer is:
Does Pressure Targeted High Flow provide enough support in premature infants?
Participants will:
Take spend 24 hours supported by Pressure Targeted High Flow and 24 hours supported by CPAP. During this time their breathing rate, oxygen requirement and other markers of comfort will be monitored.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
PTHF prior to CPAP
Procedure: Pressure Targeted High Flow
CPAP prior to PTHF
Procedure: CPAP
High Flow Nasal Cannula therapy with Pressure monitoring to match delivered CPAP pressure
Standard of care CPAP therapy
Failure of Support
Failure of respiratory support as defined by increase in fraction of inspired oxygen (FiO2) of ≥0.10, a pH of ≤7.2 with a CO2 ≥60 mm Hg, an increase in transcutaneous CO2 of ≥15mmHg above baseline or ≥2 episodes of apnea requiring positive-pressure ventilation
Time frame: 24 hours
Oxygenation
ratio of mean SpO2 to FiO2
Time frame: 24 hours
Respiratory Rate
Mean respiratory rate
Time frame: 24 hours
Infant comfort - NIPE
Newborn Infant Parasympathetic Evaluation
Time frame: 24 hours
Infant Comfort - Parent
Parental Questionnaire
Time frame: 24 hours
Resource Use
Number of handling/repositioning episodes by nurse/respiratory therapist
Time frame: 24 hours
Plan to share: Undecided — Happy to share IPD if a need arises
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Aug 2027, 15 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas at Austin →